Actively Recruiting
DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins
Led by M.D. Anderson Cancer Center · Updated on 2026-04-09
60
Participants Needed
1
Research Sites
315 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical research study is to learn if a handheld Mass Spectrometry device (MasSpec Pen) can accurately distinguish between masses, neurofibroma, and normal tissue during surgery.
CONDITIONS
Official Title
DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with MPNST or neurofibroma and scheduled for surgical removal as part of standard care
- Age 1 year or older (includes children and adults)
- Have at least one measurable tumor lesion 1 cm or larger confirmed by CT scan, MRI, or clinical exam
- Have recurrent or primary disease
- Adults (over 18 years) must be able and willing to sign informed consent
- English and non-English speaking patients can participate
You will not qualify if you...
- Adults with cognitive impairment requiring a legal representative for consent
- Patients younger than 1 year old or neonates
- Pregnant patients undergoing surgery for MPNST
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States, 77090
Actively Recruiting
Research Team
K
Keila Torres, MD,PHD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here